Nathan Pate

Frederick National Laboratory for Cancer Research — United States

Medicine · Health Sciences

7h-index536citations70works0.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(15), Lung Cancer Treatments and Mutations(15), Cancer Research and Treatments(11), CAR-T cell therapy research(9), Molecular Biology Techniques and Applications(7)

Publications70 total

Infertility and periocular swelling in a female zebra finch (Taeniopygia guttata)
Journal of the American Veterinary Medical Association·2024· 1 cited
FIGURE 4 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
Data from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
FIGURE 5 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
FIGURE 1 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
FIGURE 2 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
FIGURE 3 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
Supplementary Table from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
Supplementary Table from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024· 1 citedOpen Access
FIGURE 4 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
FIGURE 1 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
FIGURE 2 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
FIGURE 3 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
FIGURE 5 from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
Data from Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
2024Open Access
Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer
Cancer Research Communications·2024· 3 citedOpen Access
CD8 T-cell dysfunction is linked with CAR T-cell failure and can be mitigated by a non-alpha IL-2 agonist, pegenzileukin
2023· 1 citedOpen Access
S259: SAR444245, A NON-ALPHA IL2, RESCUES CHRONIC ANTIGEN- AND CAR-DRIVEN T-CELL DYSFUNCTION
HemaSphere·2023Open Access
Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation
American Journal of Respiratory Cell and Molecular Biology·2023· 21 cited
SAR444245, a non‐alpha IL2, rescues chronic antigen and CAR‐driven T‐cell dysfunction
Hematological Oncology·2023Open Access
page 1 of 4Next →

Frequent Co-authors

Zoë Weaver Ohler(27), Rajaâ El Meskini(21), Devon Atkinson(21), Amanda Day(16), Theresa M. Guerin(14), Laura Bassel(13), Nitin Roper(11), Tapan K. Maity(11), Constance M. Cultraro(11), Svetlana Pack(11), Valerie Zgonc(11), Udayan Guha(11), Alan Kulaga(10), Abdalla Abdelmaksoud(10), Michelle Gumprecht(10), Susana Hayes(10), Michael D. Oberst(10), Ian M. Kaplan(10), Patrick Raber(10), Terry Van Dyke(10)